Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: A phase i trial of combined induction therapy and bortezomib consolidation

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 497-502

  Roy, Rupali ^a   Evens, Andrew M ^b   Patton, David ^a   Gallot, Lillia ^a   Larson, Annette ^b   Rademaker, Alfred ^a   Cilley, Jeffrey ^a   Spies, Stewart ^a   Variakojis, Daina ^a   Gordon, Leo I ^a   Winter, Jane N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Follicular lymphoma; Y 90 ibritumomab tiuxetan

Indexed keywords

BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; PYRAZINES; RADIOIMMUNOTHERAPY; RECURRENCE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84873375468     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.722215     Document Type: Article

References (27)

1. 131I-tositumomab therapy as initial therapy for follicular lymphoma. N Engl J Med 2005: 352: 441-9.
2. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005: 23: 7565-7573.
3. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99: 4336-4342.
4. Witzig TE, Flinn IW, Gordon LI, et al. Treatmentwithibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20: 3262-3269.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of ytrrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20: 2453-2463.
6. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26: 5156-5164.
7. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50: 183-193.
8. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteosome inhibitor PS-341: implications for systemic nuclear factor-kB inhibition. Cancer Res 2001: 61: 3535-3540.
9. Pervan M, Calimlim J, Matso D, et al. Active comibination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo dif use large B-cell lymphoma model. Blood 2005: 106(Suppl. 1): Abstract 2406.
10. Heckman CA, Mehew JW, Boxer LM. NF-kappaB activates Bcl-2 expressionint(14;18) lymphoma cells. Oncogene 2002;21: 3898-3908.
11. Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Hematol 2009;146: 652-655.
12. DiBella N, Taetle R, Kolibaba K, et al. Resultsofaphase2 studyof bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010;115: 475-480.
13. O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010;6: 719-726.
14. Craig M, Hanna WT, Cabanillas F, et al. Bortezomibincombination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma: results of a phase 2 study. Blood 2010: 116(Suppl. 1): Abstract 2798.
15. Coifer B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011;12: 773-784.
16. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117: 2807-2812.
17. Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase IIVERTICAL study. J Clin Oncol 2011;29: 3389-3395.
18. deVos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009;27: 5023-5030.
19. Cheson BD, Pfstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25: 579-586.
20. Enrico O, Gabriele B, Nadia C, et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007: 138: 396-397.
21. Nowis D, Maczewski M, Mackiewicz U, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010: 176: 2658-2668.
22. Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma 2004;4: 230-237.
23. O'Connor OA. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 2005: 6: 191-199.
24. Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2010 Dec 14. [Epub ahead of print]
25. Zinzani PL, Gandolf L, Stenfoni V, et al. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk 2010;10: 258-261.
26. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999: 17: 3793-3803.
27. Beaven AW, Shea TC, Moore DT, et al. A phase I study evaluating ibritumomab tiuxetan (Zevalin) in combination with bortezomib (Velcade) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lympoma 2012;53: 254-258.